Worse Survival in Elderly Patients with Extremity Soft-Tissue Sarcoma

• Published in: Annals of surgical oncology Vol. 23; no. 8; pp. 2577 - 2585
• Main Authors: Hoven-Gondrie, Miriam L., Bastiaannet, Esther, Ho, Vincent K.Y., van Leeuwen, Barbara L., Liefers, Gerrit-Jan, Hoekstra, Harald J., Suurmeijer, Albert J. H.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.08.2016; Springer Nature B.V
• Subjects: Age Factors; Aged; Aged, 80 and over; Bone and Soft Tissue Sarcomas; Combined Modality Therapy; Extremities - pathology; Female; Follow-Up Studies; Humans; Male; Medicine; Medicine & Public Health; Netherlands; Oncology; Prognosis; Registries - statistics & numerical data; Risk Factors; Sarcoma - mortality; Sarcoma - pathology; Sarcoma - therapy; Surgery; Surgical Oncology; Survival Rate; Relative Survival; Sarcoma; Relative Excess Risk; Clear Cell Sarcoma; Isolate Limb Perfusion
• ISSN: 1068-9265; 1534-4681
• DOI: 10.1245/s10434-016-5158-7

Background Nearly half of soft-tissue sarcoma (STS) patients are over the age of 65, and the behavior of cancer in these elderly patients is poorly understood. The aim of this study was to assess the impact of age, sarcoma histotype, grade, stage, and treatment modalities on survival of extremity STS (ESTS) patients. Methods Patients ≥18 years diagnosed with ESTS between 1989 and 2008 were selected from the Netherlands Cancer Registry. Survival rates and patient and treatment characteristics were analyzed for all patients. Relative survival and relative excess risk of death were estimated for young (<65 years) and older (>65 years) patients. Results Overall, 3066 patients were included in this study. Histotype was different between young (<65 years) and elderly (>65 years) patients ( p  < 0.001). Patients over the age of 65 were more often diagnosed with high-stage ESTS and an increasing proportion of high-grade ESTS ( p  < 0.001). The proportion of patients who received no treatment increased with age, and the elderly received fewer combined-modality treatments. Age was significantly associated with relative 5-year survival [72.7 % for younger patients and 43.8 % for the oldest elderly (>85 years)]. In multivariable analysis, age still remained a significant prognostic factor. Conclusions Different distribution of sarcoma histotypes, more high-stage and high-grade sarcomas at diagnosis, less aggressive treatment, and worse survival rates emphasize the need for optimizing sarcoma research and care of the elderly.